OPENING A NEW DOOR

to Personalized Treatment for Women with Ovarian Cancer


Why BRCA Mutations Matter in the Battle Against Ovarian Cancer

Harmful mutations in the BRCA1 and BRCA2 genes increase a woman's risk of developing ovarian cancer.¹

For women diagnosed with ovarian cancer, knowing their BRCA status – whether or not they have deleterious BRCA1 or BRCA2 mutations – at the time of diagnosis is important for personalizing cancer treatment therapy. The majority of women with advanced ovarian cancer will have a reoccurrence of their cancer, so understanding the full range of treatment options is important.²



75% of all women with ovarian cancer don't know their BRCA status³



About 15% of women with ovarian cancer are BRCA-positive (have mutations in the BRCA1 or BRCA2 genes)⁴



44% of women with BRCA-positive ovarian cancer have no family history of cancer⁴

Knowing BRCA Status is the Key to Unlocking a New Treatment Option

BRACAnalysis CDx is a **highly accurate** companion diagnostic test that identifies harmful or potentially harmful mutations in the BRCA1 and BRCA2 genes using DNA from a blood sample in order to determine a woman's BRCA status.



What is a Companion Diagnostic?

A companion diagnostic is a test that helps doctors decide which patients could be helped by a drug and which patients would not benefit. A companion diagnostic is designed to be paired with a specific drug or therapy.⁵

The New Door in Personalized Ovarian Cancer Treatment

Lynparza™ (olaparib) is the first and only FDA-approved poly ADP-ribose polymerase (PARP) inhibitor for advanced ovarian cancer patients with germline BRCA1/2 mutations who have completed three or more lines of chemotherapy.

BRACAnalysis CDx is the first and only FDA-approved companion diagnostic that has been proven to effectively identify BRCA-positive ovarian cancer patients who are eligible for treatment with Lynparza.

BRACAnalysis CDx FDA-APPROVED

as a companion diagnostic to


LYNPARZA

For more detailed information about Lynparza and its safety and efficacy please visit lynparza.com.

For full intended use and other information about BRACAnalysis CDx please visit myriadpro.com/bracanalysis-cdx.

BRCA Status Is the Key to the Door for Lynparza

Learn more at bracnow.com.



http://www.cancer.gov/cancertopics/genetics/brca-fact-sheet#r1.

Ovarian Cancer National Alliance. Treatment. Available at http://www.ovariancancer.org/about/treatment/

³Myriad Genetics. Data on file

*Alsop K, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663.

⁵U.S. Food and Drug Administration. Personalized medicine and companion diagnostics go hand-in-hand. Available at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm407328.htm.



Trademarks: Unauthorized use of any Myriad trademark, service mark, or logo may be a violation of federal and state trademark law. Products, service marks or logos referenced by the Myriad company fact sheet are either trademarks or registered trademarks of Myriad and/or its affiliates in the United States and other countries. Lynparza is a registered trademark of AstraZeneca.

